Introduction
Since the late 1970s bisphosphonates have been part of oncological therapy, with the benefi ts of a signifi cant reduction of bone pain and skeletal-related events (SRE) in patients with metastatic bone disease secondary to multiple myeloma, breast cancer or prostate cancer. Skeletal-related events include any secondary complication from the presence of bone metastases such as radiation therapy to reduce pain or prevent fracture, bone surgery to treat or prevent fractures, and pathologic fracture or spinal cord compression that can result in paraesthesias, incontinence, and paralysis [1, 2] . Over the past few years, because of growing positive clinical evidence, the use of bisphosphonates dramatically increased, especially in cases of osteoporosis and of course also in patients with bone metastases of all cancer types. In 2003 the fi rst cases of osteonecrosis of the jaw (ONJ) were published and identifi ed as an adverse eff ect of the bisphosphonate therapy, mainly occurring during or after intravenous bisphosphonate therapy with the more potent agents pamidronate and zoledronate [3, 4] .
In spite of the great number of patients receiving bisphosphonates, osteonecrosis of the jaw is a rather rare complication. But if exclusively the intravenous applications are focused on, the risk of ONJ appears quite high, especially when particular trigger factors are involved. Once patients are suff ering from osteonecrosis, therapeutic management can be very challenging and advanced disease signifi cantly impacts the quality of life. Numerous clinical trials are running as shown in Table 1 to identify and evaluate risk or trigger factors as well as to develop evidence based therapeutic approaches.
Th e fi rst case of osteonecrosis of the jaw in our oncological department was a patient with multiple myeloma and long-term intravenous bisphosphonate treatment. Figure 1 is an impressive 3D reconstruction of CT images of the cranium of this patient with the osteonecrotic lesion in the maxilla and the destructed anterior wall of left maxillary sinus.
Risk factors
Until recently osteonecrosis of the jaw was seen solely in its relationship to bisphosphonate therapy. Its infl uence on wound healing and bone remodelling, along with its anti-angiogenic properties, conclusively explained the pathophysiological aspects of the inability to deal with mucosal or bone damage. Lately, denosumab, a human monoclonal antibody inhibiting the receptor activator of nuclear factor κ B ligand (RANKL), has proven to be at least noninferior to zoledronic acid in delaying or preventing skeletal-related events. Th ree similarly designed prospective trials including more than 5,700 patients suff ering from bone metastases secondary to diff erent cancer types have shown quite similar rates of overall adverse events, with a comparatively low incidence of 1.0 to 2.0 per cent ONJ but a higher risk by trend for denosumab therapy [5] [6] [7] .
Osteonecrosis of the jaw usually commences in the alveolar bone and then spreads into the jaws [8] . With an approximate ratio of 2 to 1, osteonecrotic lesions more commonly appear in the mandible than in the maxilla. Individual cases are reported with osteonecrosis of the skull base or the auditory canal [9, 10] , but to date there is no evidence for any manifestation outside of the craniofacial area. Th ere are some reports of atypical femoral fractures in long term bisphosphonate therapy in patients with osteoporosis [11] . Th is raises the question as to whether there are structural diff erences or special conditions which promote osteonecrosis in these preferred locations.
First of all, bone turnover is reported to be up to ten times higher in the alveolar bone than in other bones. As we know that bisphosphonates persist for years in the skeleton and are mainly stored in bones with a high turnover rate, we can assume that the concentration within the jaws is much higher than that in the limbs and vertebrae. Also the greater vascularisation of the jaws may have an impact on the described accumulation. Another peculiarity is that the alveolar bones have only a slight mucoperiostal cover, whereas other bones are protected by a deep covering of soft tissue. Furthermore, bone cells in other localisation are diff erent from those in the alveolar bone, e.g. osteoblasts located in the alveolar region divide signifi cantly faster than osteoblasts in other bones [12] . In addition, many authors assume an infl uence of the oral microenvironment; some interesting data exist for actinomyces. Many actinomyces species are opportunistic pathogens. Hansen et al. analyzed 45 cases of actinomycosis of the jaw and identifi ed in a vast majority of the patients osteonecrotic bone lesions (ONJ in 58.7%, infected osteoradionecrosis in 35.6%). Actinomycosis of the jaw seems to be a rare condition in patients without any anti-tumor therapy (only three patients out of 45, 6 .7%), so that a strong connection between this infection and the bone lesions can be presumed [13] . Whether actinomycosis facilitates the development of osteonecrosis or has to be considered as an opportunistic infection needs further investigation. Looking at the diff erences between mandible and maxilla, there is an interesting aspect regarding vascularisation. Th e maxilla, mainly consisting of spongiosa, has a better blood supply than the mandible, with its very strong corticalis in relation to the whole structure. Th is could explain the higher incidence of ONJ in the mandible and also the often more complicated courses of disease [14, 15] .
Several additional factors have been identifi ed which may potentiate the risk of developing ONJ. As drug-related factors, bisphosphonate potency and duration of therapy have a big infl uence. Also local risk factors, including dentoalveolar surgery (Tab. 2), the already mentioned anatomical specialities of alveolar bone and concomitant oral diseasefor example, periodontal and dental abscesses -have to be mentioned. Furthermore, demographic and systemic factors such as age (several studies report increasing age as consistently associated with ONJ) [16, 17] , race (Caucasians more than African Americans) [17, 18] and cancer diagnosis, as well as epigenetic associations [19] may infl uence the risk of osteonecrosis. Life style and behavioural factors (obesity, tobacco, alcohol) are also proposed to play a role [16] . Th e probably most important risk factors for ONJ are intravenous bisphosphonate exposure and dentoalveolar procedures [20, 21] .
Role of bisphosphonates
Bisphosphonates play a major role in the treatment of metastatic bone disease as well as in osteoporosis. Th ey accumulate in bones, and once integrated into the bone matrix they can persist for years. Several theories exist which attempt to explain the pathogenesis of bisphosphonate-related ONJ, but a defi nitive cause-and-eff ect relationship is still missing. Probably it is a multifactorial process: Of primary signifi cance is the jaw's susceptibility in combination with the oral microenvironment, as described above; then the anti-osteoclast activity of bisphosphonates; and additionally anti-angiogenic eff ects caused by the depression of blood fl ow and decrease of VEGF [14, [22] [23] [24] . Bisphosphonate treatment generally also leads to an inability of the bone to respond to injury, and to a slowdown of the natural bone remodelling process. Th e theory of slowed remodelling as the main cause of osteonecrosis is discussed highly controversial at the moment as there is compelling evidence that bone turnover is not reduced within ONJ lesions. Furthermore other clinical conditions with reduced bone turnover such as hypoparathyroidism are not associated with development of osteonecrosis [25] .
Th e estimated risk of contracting ONJ depends on the type of bisphosphonate therapy. In osteoporotic patients (mainly women) on oral bisphosphonates the risk varies from 1 in 10,000 to 1 in 100,000 [21] . Th e risk increases with the above-mentioned triggering factors, with dental extraction as the most important, to 1 in 300 to 1,000. With intravenous bisphosphonate treatment 1 to 10 per cent of patients who have had a dental extraction develop ONJ [26] .
Role of denosumab
In the last few years denosumab, a fully human monoclonal antibody against RANK ligand, was evaluated in three similarly designed randomized double-blinded phase III trials and compared to zoledronic acid, the bisphosphonate most often used in metastatic bone disease. Whereas the standard therapy with intravenous bisphosphonate has some notable side eff ects, such as renal impairment und acute fl u-like symptoms, denosumab usually is well tolerated, not requiring renal monitoring or dose adjustment.
In breast cancer patients with bone metastases denosumab therapy showed a statistically signifi cant delay of time to fi rst on-study SRE (HR 0.82, CI 0.71 to 0.95, p = 0.01), to subsequent on-study SREs (rate ratio 0.77, CI 0.66 to 0.89, p = 0.001) and also a greater reduction in bone turnover markers compared to zoledronic acid, and it was therefore estimated superior to the standard therapy [5] . In a second clinical trial with a quite similar setting, comparing monthly denosumab therapy to zoledronic acid in patients with bone metastases from solid tumours (except prostate cancer and breast cancer) or multiple myeloma, denosumab was at least noninferior, and drug safety was quite similar. Because of a higher mortality under denosumab treatment (HR 2.26; 95% CI 1.13 to 4.50) in a subgroup analysis of 180 myeloma patients [6] , the US Food and Drug Administration (FDA) and also the European Medicines Agency (EMEA) approved the RANKL-inhibitor only for patients with bone metastases from solid tumors but not multiple myeloma.
A third trial, published in Lancet in February 2011, which included 1,904 men with castration-resistant prostate cancer, also showed a signifi cant reduction of SREs with monthly denosumab [7] .
In the above prospective trials the safety profi le was very interesting. Both therapy arms showed quite similar rates of overall adverse events. Whereas hypocalcaemia more often occurred under the antibody therapy, acute-phase reactions were more common with zoledronic acid. In spite of the routine dose adaption of zoledronic acid in patients with renal insuffi ciency there was a trend towards more renal adverse events with zoledronic acid. In the breast cancer trial adverse events associated with renal toxicity were statistically signifi cantly more frequent in the zoledronic acid therapy arm. Risk of ONJ as the probably most important side-eff ect of the two medications was 1 to 2 per cent, and statistically there was no diff erence in the incidence, although in two trials there was at least a trend towards more osteonecrotic lesions under denosumab [5] [6] [7] . Median time on study was between seven months (multiple myeloma or advanced cancer excluding breast and prostate cancer) and 17 months (breast cancer). As a traceable argument Fusco et al. refer to the quite short follow-up in the trials mentioned and therefore assume an underestimation of ONJ in both therapy arms [27] . Post marketing further investigation is needed to show which bone remodelling drug more increases the risk for ONJ in clinical practice. Before Amgen's clinical trial program for denosumab somebody could argument that ONJ is a specifi c toxicity related to the presence of bisphosphonate in bone. However, with the more or less equal rates of osteonecrosis in both treatment arms this theory has failed.
Immunosuppression and anti-angiogenic treatment
Diabetes mellitus, with its impact on wound healing and periodontal disease, as well as the associated immune defi ciency, is a discussed risk factor for developing ONJ. Microvascular ischemia, decreased bone turnover and endothelial cell dysfunction are other possible interrelated factors.
Severely suppressed bone turnover, also described as bone freezing, is a situation defi ned as very low bone turn over with normally progressing mineralisation. Th is destabilization probably causes atypical fractures for example in the femoral shaft such as seen in patients on long-term bisphosphonate treatment [28] and perhaps also aff ects ONJ development.
Khamaisi et al. showed a signifi cantly higher proportion of diabetes patients in a group of 31 consecutive ONJ patients (58%) than in the general population (14%) or in an oncological control group without ONJ under bisphosphonate treatment [29] . But with only one retrospective analysis up until now, there is actually insuffi cient evidence to prove this relationship.
Chemotherapy and the subsequent immunosuppression are further potential risk factors, although it is very difficult to estimate its infl uence because of the mostly simultaneous application of bisphosphonates. Prospective data analyzing the role of chemotherapy in ONJ are not available. In preclinical models bisphosphonates are able to stimulate other than bone cells, especially immune-modulating cells, such as bone marrow monocytes and dendritic cells [30, 31] . Th erefore further investigation is needed to evaluate the infl uence of immunosuppression on the risk of osteonecrosis. Corticosteroids, a common co-medication in oncological patients and one of the signifi cant risk factors for osteoporosis when used as a long-term therapy, lead to an increased susceptibility to infection and delayed wound healing. Steroid-induced osteonecrosis is a common adverse event, especially in the femoral head, but occasionally also aff ecting other bone sites. As is the case with ONJ, its aetiology and pathophysiology are not suffi ciently understood.
Bi et al. developed the fi rst mouse model of bisphosphonate-associated osteonecrosis of the jaw, showing that the development of osteonecrotic lesions and impaired soft tissue healing is one long-term side eff ect not only of the use of high-dose bisphosphonates, but also of immunosuppressive and chemotherapy drugs, as well as mechanical trauma. Th e authors are confi dent that this mouse model will lead to a better understanding of the aetiology of ONJ and the relevance of the discussed risk factors [32] .
Estilo et al. recently presented a case report of ONJ with exposed and necrotic bone lesions in two patients without histories of oral or intravenous bisphosphonates. Both had been treated with bevacizumab as part of their oncological therapies. One of them, a 51-year-old woman with a history of breast cancer and chest wall recurrence, had been given eight doses of bevacizumab in combination with capecitabine. Th e other, a 33-year-old woman, was treated with bevacizumab after subtotal resection of glioblastoma multiforme, followed by simultaneous radiochemotherapy [33] .
Th ere is now increasing evidence that bevacizumab as well as sunitinib, both aff ecting angiogenesis by inhibiting the action of the vascular endothelial growth factor (VEGF), may independently increase or contribute to the risk of ONJ [34] [35] [36] .
Staging and treatment
In 2006 the American Association of Oral and Maxillofacial Surgeons (AAOMS) developed a position paper to pool the proven knowledge and make it available to interested clinicians. Th e initial 2006 recommendations were revised and published in a 2009 update [20] . Th e AAOMS proposes that patients should be considered to have bisphosphonate-related osteonecrosis of the jaw if all of the following three conditions apply:
• current or previous treatment with bisphosphonates; • exposed, necrotic bone in the maxillofacial region persisting for more than eight weeks; • no history of radiation therapy of the jaws.
Several other professional associations have defi ned the clinical term "osteonecrosis of the jaw", and although they have some diff erences in detail, all involve a mucosal wound with exposed bone that fails to heal in six to eight weeks and all exclude a history of head and neck radiation [37, 38] . Patients at risk during or after bisphosphonate medication who present with unspecifi c symptoms such as pain, tooth mobility, mucosal swelling, erythema or ulceration have per defi nition stage 0 osteonecrosis of the jaw, and therefore symptomatic treatment and sometimes systemic pain medication or antibiotics are necessary [20] .
Once suff ering from osteonecrosis with exposed and necrotic bone lesions, therapeutic management can be very challenging, and advanced disease signifi cantly impacts quality of life. Stopping intravenous bisphosphonate treatment has no short-term benefi ts because of the prolonged bone half-life, but it may help control the problem in the longterm. Regarding denosumab evidence and guidelines are missing, but in our opinion drug holiday or discontinuation of treatment of course must be considered.
Probably the main treatment goal is to preserve quality of life by reducing pain, managing infection and preventing the extension of the bone lesion and development of new areas of necrosis [20, 22] . Diff erent treatment strategies depend on the stage of osteonecrosis and the disease burden, and range from patient education and antibacterial mouth rinse to systemic management including oral antibiotics and pain medication. In an advanced state of disease, surgical debridement or resection of necrotic lesions is helpful in long-term control [15, [20] [21] [22] 39] .
Eckhardt et al. from Department of Cranio-Maxillofacial Surgery of Hannover Medical School evaluated 142 Patients suff ering from ONJ, of whom 86% required surgical treatment. Depending on the clinical situation transoral sequestrectomy, marginal bone resection or in case of extensive osteonecrosis or pathologic fracture of the mandible, a continuity resection of the involved mandible and fi xation with titanium reconstruction plates were performed. If tension-free soft-tissue closure is not possible, a myofascial fl ap from the mylohyoid muscle was the method of choice to close the softtissue defects [40] . Recently Nocini et al. demonstrated that microsurgical reconstruction of the mandible is a feasible strategy in extensive mandibular osteonecrosis [41] .
Th ere is plenty of room for innovative therapy approaches. For example an interesting case report of Cheung and Seeman in 2010 showed healing of an osteonecrotic mandibular lesion after 8 weeks of teriparatide treatment [42] , a recombinant human parathyroid hormone which is currently evaluated as antiresorptive agent in glucocorticoidinduced osteoporosis. Of course this is only a case report, and one has to argue that metastatic bone disease and also for example radiotherapy of the skeleton are contraindications to the use of teriparatide. Furthermore there are safety concerns regarding osteosarcoma [43, 44] .
Prevention
However, because of the all in all disappointing therapeutic possibilities we should especially focus on avoiding the development of osteonecrosis. It is widely accepted that preventive dental treatment signifi cantly reduces risk [45, 46] . Th erefore AAOMS recommends dental evaluations and completing of necessary treatment before initiating intravenous bisphosphonate therapy. Another important pre-condition is waiting for the complete healing of mucosal wounds. In addition, patients with dentures should undergo frequent examinations for areas of mucosal damage, and proper education of the patients is very important [20] . Good oral health and routine dental care are recommended for all patients with antiresorptive therapy. Because of the long bisphosphonate half-lives once they are incorporated into the bones, many consensus statements recommend a discontinuation of medication, or at least an extension of dosing-intervals, after two years of monthly bisphosphonate treatment [37, 47] . While waiting for more denosumab data similar prevention strategies appear appropriate for each antiresorptive therapy [48] .
Specifi c serum tests like morning fasting C-terminal telopeptide bone suppression marker (CTX) are currently evaluated as possible predictor of ONJ risk but there is not enough evidence yet to adapt or interrupt antiresorptive therapy because of low CTX serum values in daily clinical practice [48] .
Prospects
Animal models and new study approaches should lead to a better understanding of the mechanisms of ONJ, thus enabling us to defi ne all important risk factors and their specifi c infl uences on its development. Th is can help researchers develop risk-adapted treatment strategies in metastatic bone disease. Further investigations are necessary to answer the remaining questions, for example whether alternative dosing schedules with lower doses or extended interval dosing either of bisphosphonates or denosumab could increase drug safety. In daily practice frequent and standardized monitoring of patients at risk is very important. Some guidelines and recommendations accept bisphosphonates and denosumab as comparable options for antiresorptive treatment in metastatic bone disease secondary to solid tumors. In case of renal insuffi ciency denosumab shortly will displace the bisphosphonates. But in our opinion the effi cacy and safety of denosumab must be evaluated in a long-term clinical setting before this new drug will be widely accepted to replace the bisphosphonates as a standard therapy in metastatic bone disease.
Take-home message
Osteonecrosis of the jaw is a severe complication in oncological settings which signifi cantly impacts the quality of life. Patients at risk should be monitored frequently because beside bisphosphonates several other drugs are under suspicion of inducing osteonecrosis or at least potentiating the risk in combination with bisphosphonates. Preventive dental treatment signifi cantly reduces risk.
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